logo-loader
Anavex Life Sciences

Anavex Life's Alzheimer's drug awarded orphan status for child seizures

Anavex 2-73 is the company’s lead candidate and currently in a Phase 2a clinical trial for Alzheimer’s disease.

Picture of brain
Infantile spasms usually affect babies

Anavex Life Sciences Corp (Nasdaq:AVXL) has received US orphan drug status in infantile spasms for  a drug it is currently trialing to ease Alzheimer’s.

Anavex 2-73 is the second of the company’s projects to get ODD status, a designation the US Food and Drug Administration awards to fast track treatments for diseases that affect fewer than 200,000 people.

It gives Anavex a seven year window of commercial exclusivity in the US in the area of infantile spasms, prioritized consultation by the FDA on clinical studies and exemptions on some regulatory fees.

An infantile spasm is a specific type of seizure usually in the first year of life and typically between the ages of 4-8 months. Roughly 2-3 babies per 10,000 get them, with peak incidence at 6 months of age and less than 10% of cases presenting after 12 months of age.

Children with symptomatic spasms more frequently exhibit neurological deficits and cognitive and developmental delays, the company said.

Anavex 2-73 is the company’s lead candidate and currently in a Phase 2a clinical trial for Alzheimer’s disease. 

Quick facts: Anavex Life Sciences

Price: $2.71

Market: NASDAQ
Market Cap: $142.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 9 hours ago

2 min read